Advances in the pharmacological management of non-24-h sleep-wake disorder

References

• Abbott SM. Non-24-hour sleep-wake rhythm disorder. Neurol Clin. 2019 Aug;37(3):545–552.
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Newsome DA. Different types of melatonin circadian secretory rhythms in some blind subjects. J Clin Endocrinol Metab. 1983 Jun;56(6):1103–1107.
   PubMed Web of Science ®Google Scholar
• Sack RL, Lewy AJ, Blood ML, et al. Circadian rhythm abnormalities in totally blind people: incidence and clinical significance. J Clin Endocrinol Metab. 1992 Jul;75(1):127–134.
   PubMed Web of Science ®Google Scholar
• Auger RR, Burgess HJ, Emens JS, et al. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An update for 2015: an american academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2015 Oct 15;11(10):1199–1236.
   PubMed Web of Science ®Google Scholar
• Lockley SW, Arendt J, Skene DJ. Visual impairment and circadian rhythm disorders. Dialogues Clin Neurosci. 2007;9(3):301–314.
   PubMedGoogle Scholar
• Uchiyama M, Lockley SW. Non-24-hour sleep-wake rhythm disorder in sighted and blind patients. Sleep Med Clin. 2015 Dec;10(4):495–516.
   PubMed Web of Science ®Google Scholar
• Emens JS, Eastman CI. Diagnosis and treatment of non-24-h sleep-wake disorder in the blind. Drugs. 2017 Apr;77(6):637–650.
   PubMed Web of Science ®Google Scholar
• Garbazza C. Non 24-hour sleep-wake disorder in sighted patients: dealing with an orphan disease. J Clin Sleep Med. 2018 Aug 15;14(8):1445–1446.
   PubMed Web of Science ®Google Scholar
• Solaiman SS, Agrawal R. Non-24-hour sleep-wake circadian rhythm disorder in a sighted male with normal functioning. J Clin Sleep Med. 2018 Mar 15;14(3):483–484.
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Uchiyama M, Kamei Y, et al. Clinical analyses of sighted patients with non-24-hour sleep-wake syndrome: a study of 57 consecutively diagnosed cases. Sleep. 2005 Aug 1;28(8):945–952.
   PubMed Web of Science ®Google Scholar
• Okawa M, Uchiyama M. Circadian rhythm sleep disorders: characteristics and entrainment pathology in delayed sleep phase and non-24 sleep–wake syndrome. Sleep Med Rev. 2007;11(6):485–496.
   PubMed Web of Science ®Google Scholar
• Johnsa JD, Neville MW. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder. Ann Pharmacother. 2014 Dec;48(12):1636–1641.
   PubMed Web of Science ®Google Scholar
• Nishimon S, Nishimon M, Nishino S. Tasimelteon for treating non-24-h sleep-wake rhythm disorder. Expert Opin Pharmacother. 2019 Jun;20(9):1065–1073.
   PubMed Web of Science ®Google Scholar
• Welsh DK, Takahashi JS, Kay SA. Suprachiasmatic nucleus: cell autonomy and network properties. Annu Rev Physiol. 2010;72(1):551–577.
   PubMed Web of Science ®Google Scholar
• Quera Salva MA, Hartley S, Leger D, et al. Non-24-hour sleep-wake rhythm disorder in the totally blind: diagnosis and management. Front Neurol. 2017;8:686.
   PubMed Web of Science ®Google Scholar
• Berry RB, Wagner MH. Sleep Medicine Pearls, Third Edition. Amsterdam: Elsevier. 2015..
   Google Scholar
• Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science. 1999 Jun 25;284(5423):2177–2181.
   PubMed Web of Science ®Google Scholar
• Lamba P, Bilodeau-Wentworth D, Emery P, et al. Morning and evening oscillators cooperate to reset circadian behavior in response to light input. Cell Rep. 2014 May 8;7(3):601–608.
   PubMed Web of Science ®Google Scholar
• Czeisler CA, Allan JS, Strogatz SH, et al. Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. Science. 1986 Aug 8;233(4764):667–671.
   PubMed Web of Science ®Google Scholar
• Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science. 2002 Feb 8;295(5557):1070–1073.
   PubMed Web of Science ®Google Scholar
• Hattar S, Liao HW, Takao M, et al. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science. 2002 Feb 8;295(5557):1065–1070.
   PubMed Web of Science ®Google Scholar
• Moore RY. Neural control of the pineal gland. Behav Brain Res. 1996;73(1–2):125–130.
   PubMed Web of Science ®Google Scholar
• Claustrat B, Melatonin LJ. Physiological effects in humans. Neurochirurgie. 2015 Apr-Jun;61(2–3):77–84.
   PubMed Web of Science ®Google Scholar
• Reiter RJ. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol. 1991 Aug;79(1–3):C153–8.
   PubMed Web of Science ®Google Scholar
• Liu J, Clough SJ, Hutchinson AJ, et al. MT1and MT2 melatonin receptors: a therapeutic perspective. Annu Rev Pharmacol Toxicol. 2016;56(1):361–383.
   PubMed Web of Science ®Google Scholar
• Foulkes NS, Borjigin J, Snyder SH, et al. Rhythmic transcription: the molecular basis of circadian melatonin synthesis. Trends Neurosci. 1997 Oct;20(10):487–492.
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Sack RL, Blood ML, et al. Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans. Ciba Found Symp. discussion 317-21. 2010;72: 551–577.
   Google Scholar
• Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int J Clin Pract. 2007 May;61(5):835–845.
   PubMed Web of Science ®Google Scholar
• Alarma-Estrany P, Pintor J. Melatonin receptors in the eye: location, second messengers and role in ocular physiology. Pharmacol Ther. 2007 Mar;113(3):507–522.
   PubMed Web of Science ®Google Scholar
• Zlotos DP, Jockers R, Cecon E, et al. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161–3185.
   PubMed Web of Science ®Google Scholar
• Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, et al. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012 Apr 4;351(2):152–166.
   PubMed Web of Science ®Google Scholar
• Esrefoglu M, Seyhan M, Gul M, et al. Potent therapeutic effect of melatonin on aging skin in pinealectomized rats. J Pineal Res. 2005 Oct;39(3):231–237.
   PubMed Web of Science ®Google Scholar
• Balik A, Kretschmannova K, Mazna P, et al. Melatonin action in neonatal gonadotrophs. Physiol Res. 2004;53 Suppl 1(Suppl 1):S153–66.
   PubMed Web of Science ®Google Scholar
• Girouard H, Chulak C, Lejossec M, et al. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. J Hypertens. 2001 Aug;19(8):1369–1377.
   PubMed Web of Science ®Google Scholar
• Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet. 1978 Oct 14;2(8094):814–816. London, England
   PubMed Web of Science ®Google Scholar
• Maestroni GJ, Conti A, Pierpaoli W. Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol. 1986 Nov;13(1):19–30.
   PubMed Web of Science ®Google Scholar
• Slominski A, Tobin DJ, Zmijewski MA, et al. Melatonin in the skin: synthesis, metabolism and functions. Trends Endocrinol Metab. 2008 Jan;19(1):17–24.
   PubMed Web of Science ®Google Scholar
• Fischer TW, Burmeister G, Schmidt HW, et al. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004 Feb;150(2):341–345.
   PubMed Web of Science ®Google Scholar
• Slominski A, Pruski D. Melatonin inhibits proliferation and melanogenesis in rodent melanoma cells. Exp Cell Res. 1993 Jun;206(2):189–194.
   PubMed Web of Science ®Google Scholar
• Bonacci JM, Venci JV, Gandhi MA. Tasimelteon (Hetlioz): a new melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder. J Pharm Pract. 2015 Oct;28(5):473–478.
   PubMedGoogle Scholar
• American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed ed. Darien, IL: American Academy of Sleep Medicine; 2014.
   Google Scholar
• Culnan E, McCullough LM, Wyatt JK. Circadian rhythm sleep-wake phase disorders. Neurol Clin. 2019 Aug;37(3):527–543.
   PubMed Web of Science ®Google Scholar
• Zee PC, Goldstein CA. Treatment of shift work disorder and jet lag. Curr Treat Options Neurol. 2010 Sep;12(5):396–411.
   PubMed Web of Science ®Google Scholar
• Paine SJ, Fink J, Gander PH, et al. Identifying advanced and delayed sleep phase disorders in the general population: a national survey of New Zealand adults. Chronobiol Int. 2014 Jun;31(5):627–636.
   PubMed Web of Science ®Google Scholar
• Miles LE, Raynal DM, Wilson MA. Blind man living in normal society has circadian rhythms of 24.9 hours. Science. 1977 Oct 28;198(4315):421–423.
   PubMed Web of Science ®Google Scholar
• Barion A, Zee PC. A clinical approach to circadian rhythm sleep disorders. Sleep Med. 2007;8(6):566–577.
   PubMed Web of Science ®Google Scholar
• Dagan Y, Ayalon L. Case study: psychiatric misdiagnosis of non-24-hours sleep-wake schedule disorder resolved by melatonin. J Am Acad Child Adolesc Psychiatry. 2005 Dec;44(12):1271–1275.
   PubMed Web of Science ®Google Scholar
• Malkani RG, Abbott SM, Reid KJ, et al. Diagnostic and treatment challenges of sighted non-24-hour sleep-wake disorder. J Clin Sleep Med. 2018 Apr 15;14(4):603–613.
   PubMed Web of Science ®Google Scholar
• Ayturk DG, Castrucci AM, Carr DE, et al. Lack of melanopsin is associated with extreme weight loss in mice upon dietary challenge. PloS One. 2015;10(5):e0127031.
   PubMed Web of Science ®Google Scholar
• Boivin DB, James FO, Santo JB, et al. Non-24-hour sleep-wake syndrome following a car accident. Neurology. 2003 Jun 10;60(11):1841–1843.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kajimura N, Kato M, et al. Case of a non-24 h sleep-wake syndrome patient improved by phototherapy. Psychiatry Clin Neurosci. 2000 Jun;54(3):369–370.
   PubMed Web of Science ®Google Scholar
• Sack RL, Lewy AJ, Blood ML, et al. Melatonin administration to blind people: phase advances and entrainment. J Biol Rhythms. 1991 Fall;6(3):249–261.
   PubMed Web of Science ®Google Scholar
• Lockley SW, Dressman MA, Licamele L, et al., Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 386(10005): 1754–1764. 2015. .
   PubMed Web of Science ®Google Scholar
• Sack RL, Brandes RW, Kendall AR, et al. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med. 2000 Oct 12;343(15):1070–1077.
   PubMed Web of Science ®Google Scholar
• Slominski AT, Hardeland R, Zmijewski MA, et al. Melatonin: a cutaneous perspective on its production, metabolism, and functions. J Invest Dermatol. 2018 Mar;138(3):490–499.
   PubMed Web of Science ®Google Scholar
• Laudon M, Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014 Sep 9;15(9):15924–15950.
   PubMed Web of Science ®Google Scholar
• Williams WP 3rd, McLin DE 3rd, Dressman MA, et al. Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders. Pharmacotherapy. 2016 Sep;36(9):1028–1041.
   PubMed Web of Science ®Google Scholar
• van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep. 2010 Dec;33(12):1605–1614.
   PubMed Web of Science ®Google Scholar
• Zlotos DP. Recent progress in the development of agonists and antagonists for melatonin receptors. Curr Med Chem. 2012;19(21):3532–3549.
   PubMed Web of Science ®Google Scholar
• Roth T, Nir T, Zisapel N. Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial. Nat Sci Sleep. 2015;7:13–23.
   PubMed Web of Science ®Google Scholar
• Andersen LP, Gogenur I, Rosenberg J, et al. The safety of melatonin in humans. Clin Drug Investig. 2016 Mar;36(3):169–175.
   PubMed Web of Science ®Google Scholar
• Mantle D, Smits M, Boss M, et al. Efficacy and safety of supplemental melatonin for delayed sleep–wake phase disorder in children: an overview. Sleep Medicine: X.; 2020. p. 2. DOI:10.1016/j.sleepx.2019.100011.
   Google Scholar
• Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009 Feb 7;373(9662):482–491.
   PubMed Web of Science ®Google Scholar
• Melatonin, C13N16N2O2 — PubChem. National Library of Medicine. [ cited 2020 Dec 7] Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Melatonin
   Google Scholar
•  Ekmekcioglu C, Thalhammer T. Melatonin and Melatoergic Drugs in Clinical Practice. New Delhi: Springer;2014:1–15.
   Google Scholar
• Wiechmann AF. Melatonin: parallels in pineal gland and retina. Exp Eye Res. 1986 Jun;42(6):507–527.
   PubMed Web of Science ®Google Scholar
• Roseboom PH, Coon SL, Baler R, et al. Melatonin synthesis: analysis of the more than 150-fold nocturnal increase in serotonin N-acetyltransferase messenger ribonucleic acid in the rat pineal gland. Endocrinology. 1996 Jul;137(7):3033–3045.
   PubMed Web of Science ®Google Scholar
• Acuna-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014 Aug;71(16):2997–3025.
   PubMed Web of Science ®Google Scholar
• Slominski AT, Semak I, Fischer TW, et al. Metabolism of melatonin in the skin: why is it important? Exp Dermatol. 2017 Jul;26(7):563–568.
   PubMed Web of Science ®Google Scholar
• Kim TK, Kleszczynski K, Janjetovic Z, et al. Metabolism of melatonin and biological activity of intermediates of melatoninergic pathway in human skin cells. Faseb J. 2013 Jul;27(7):2742–2755.
   PubMed Web of Science ®Google Scholar
• Kim TK, Lin Z, Tidwell WJ, et al. Melatonin and its metabolites accumulate in the human epidermis in vivo and inhibit proliferation and tyrosinase activity in epidermal melanocytes in vitro. Mol Cell Endocrinol. 2015 Mar;15(404):1–8.
   Google Scholar
• Scheuer C, Pommergaard HC, Rosenberg J, et al. Effect of topical application of melatonin cream 12.5% on cognitive parameters: a randomized, placebo-controlled, double-blind crossover study in healthy volunteers. J Dermatolog Treat. 2016 Nov;27(6):488–494.
   PubMed Web of Science ®Google Scholar
• Slominski AT, Zmijewski MA, Semak I, et al. Melatonin, mitochondria, and the skin. Cell Mol Life Sci. 2017 Nov;74(21):3913–3925.
   PubMed Web of Science ®Google Scholar
• Zetner D, Andersen LP, Rosenberg J. Pharmacokinetics of Alternative Administration Routes of Melatonin: a Systematic Review. Drug Res. 2016 Apr;66(4):169–173.
   PubMed Web of Science ®Google Scholar
• Ebisawa T, Karne S, Lerner MR, et al. Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6133–6137.
   PubMed Web of Science ®Google Scholar
• Masana MI, Dubocovich ML. Melatonin receptor signaling: finding the path through the dark. Sci STKE. 2001 Nov 6;2001(107):39.
   Google Scholar
• Reppert SM, Godson C, Mahle CD, et al. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8734–8738.
   PubMed Web of Science ®Google Scholar
• Petit L, Lacroix I, de Coppet P, et al. Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3ʹ-5ʹ-monophosphate pathway. Biochem Pharmacol. 1999 Aug 15;58(4):633–639.
   PubMed Web of Science ®Google Scholar
• Hunt AE, Al-Ghoul WM, Gillette MU, et al. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol. 2001 Jan;280(1):C110–8.
   PubMed Web of Science ®Google Scholar
• Weaver DR, Rivkees SA, Reppert SM. Localization and characterization of melatonin receptors in rodent brain by in vitro autoradiography. J Neurosci. 1989 Jul;9(7):2581–2590.
   PubMed Web of Science ®Google Scholar
• Tan DX, Poeggeler B, Reiter RJ, et al. The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. 1993 Jun 15;70(1–2):65–71.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Qi W, et al. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept. 2000 May-Aug;9(3–4):160–171.
   PubMedGoogle Scholar
• Slominski A, Fischer TW, Zmijewski MA, et al. On the role of melatonin in skin physiology and pathology. Endocrine. 2005 Jul;27(2):137–148.
   PubMed Web of Science ®Google Scholar
• Witt-Enderby PA, Li PK. Melatonin receptors and ligands. Vitam Horm. 2000;58:321–354.
   PubMed Web of Science ®Google Scholar
• Dubocovich ML. Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988 Sep;246(3):902–910.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Melatonin prolonged release: in the treatment of insomnia in patients aged >/=55 years. Drugs Aging. 2012 Nov;29(11):911–923.
   PubMed Web of Science ®Google Scholar
• Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat. 2009;5:341–354.
   PubMed Web of Science ®Google Scholar
• Assessment Report for Circadin. European Medicines Agency. [ cited 2020 Dec 7] Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/circadin-epar-scientific-discussion_en.pdf
   Google Scholar
• Duffy JF, Zitting KM, Chinoy ED. Aging and Circadian Rhythms. Sleep Med Clin. 2015; Dec 10(4):423–434.
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Srinivasan V, Spence DW, et al. Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613–626.
   PubMed Web of Science ®Google Scholar
• Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014 Apr;15(4):385–392.
   PubMed Web of Science ®Google Scholar
• Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140–148.
   PubMed Web of Science ®Google Scholar
• Sateia MJ, Kirby-Long P, Taylor JL. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep Med Rev. 2008 Aug;12(4):319–332.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Prestia D, Colicchio S, et al. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010 Sep;8(3):287–304.
   PubMed Web of Science ®Google Scholar
• Norman TR, Olver JS. Agomelatine for depression: expanding the horizons? Expert Opin Pharmacother. 2019 Feb;13:1–10.
   Google Scholar
• San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry. 2008 Sep;23(6):396–402.
   PubMed Web of Science ®Google Scholar
• Ventimiglia G, Bellomi S, Barreca G, et al. Synthesis, characterization, and crystal chemistry of tasimelteon, a melatonin agonist, in its anhydrous and hemihydrate forms. J Pharm Sci. 2018;107(2):543–549.
   PubMed Web of Science ®Google Scholar
• Lavedan C, Forsberg M, Gentile AJ. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology. 2015 Apr;91:142–147.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Torres R, Dressman MA, et al. Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004–1011.
   PubMed Web of Science ®Google Scholar
• Torres R, Dressman MA, Kramer WG, et al. Absolute Bioavailability of Tasimelteon. Am J Ther. 2015 Sep-Oct;22(5):355–360.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Clarke M. Tasimelteon: first global approval. Drugs. 2014 Mar;74(4):505–511.
   PubMed Web of Science ®Google Scholar
• Torres R, Kramer WG, Baroldi P. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment. J Clin Pharmacol. 2015 May;55(5):525–533.
   PubMed Web of Science ®Google Scholar
• Lee D, Shin WC. Forced entrainment by using light therapy, modafinil and melatonin in a sighted patient with non-24-hour sleep-wake disorder. Sleep Med. 2015 Feb;16(2):305–307.
   PubMed Web of Science ®Google Scholar
• Yanagihara M, Nakamura M, Usui A, et al. The melatonin receptor agonist is effective for free-running type circadian rhythm sleep disorder: case report on two sighted patients. Tohoku J Exp Med. 2014 Oct;234(2):123–128.
   PubMed Web of Science ®Google Scholar
• Yamadera H, Takahashi K, Okawa M. A multicenter study of sleep-wake rhythm disorders: therapeutic effects of vitamin B12, bright light therapy, chronotherapy and hypnotics. Psychiatry Clin Neurosci. 1996 Aug;50(4):203–209.
   PubMed Web of Science ®Google Scholar
• Omori Y, Kanbayashi T, Sagawa Y, et al. Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation. Neuropsychiatr Dis Treat. 2018;14:1281–1286.
   PubMed Web of Science ®Google Scholar
• Matsui K, Takaesu Y, Inoue T, et al. Effect of aripiprazole on non-24-hour sleep-wake rhythm disorder comorbid with major depressive disorder: a case report. Neuropsychiatr Dis Treat. 2017;13:1367–1371.
   PubMed Web of Science ®Google Scholar
• Kurita M, Moriya T, Nishino S, et al. Non-24-hour sleep-wake syndrome improved by low-dose valproic acid: a case report. Neuropsychiatr Dis Treat. 2016;12:3199–3203.
   PubMed Web of Science ®Google Scholar
• Hetlioz(tasimelteon) is the only FDA-approved treatment for Non-24. Vanda Pharmaceuticals Inc. [ cited 2020 Dec 7] Available from: www.hetlioz.com
   Google Scholar
• Keijzer H, Smits MG, Duffy JF, et al. Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders. Sleep Med Rev. 2014 Aug;18(4):333–339.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci. 2009;119(6):821–846. .
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Bauer VK, Hasler BP, et al. Capturing the circadian rhythms of free-running blind people with 0.5 mg melatonin. Brain Res. 2001 Nov 9;918(1–2):96–100.
   PubMed Web of Science ®Google Scholar
• ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin. The france agency for food, environmental and occupational health & safety. [ cited 2020 Dec 7] Available from: www.anses.fr/fr/system/files/NUT2016SA0209.pdf
   Google Scholar